Abstract: A system and method for assisted pick-up and delivery of goods, the method including downloading an enterprise application to a computer device; registering at an enterprise platform with the enterprise application; requesting a service pick-up and drop-off with said enterprise platform; scheduling an assisted pick-up of the luggage or package; confirming the pick-up of the luggage or package at the pick-up point assigned by said enterprise platform; scheduling an assisted delivery of the luggage or package; and confirming delivery of the luggage or package at the drop-off point assigned by said enterprise platform.

Abstract: A method of treating systemic sclerosis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

Abstract: A method of identifying a subject who is likely to be responsive to a treatment comprising an inhibitor of IL1?, or predicting the responsiveness of a subject to a treatment comprising an inhibitor of IL1?, comprising providing a sample from a subject; administering the inhibitor of IL1? to the sample; measuring levels of one or more biomarkers in the sample; and determining the pharmacodynamic or the pharmacokinetic effect of the inhibitor of IL1? based on the levels of the one or more biomarkers.

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.

Abstract: A method of determining a pharmacodynamics or pharmacokinetic effect of an inhibitor of IL 1? comprising providing a sample from a subject; administering the inhibitor of IL 1? to the sample; measuring levels of one or more biomarkers in the sample; and determining the pharmacodynamic or the pharmacokinetic effect of the inhibitor of IL 1? based on the levels of the one or more biomarkers.

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.

Abstract: A method for predicting maintenance of response to IL-23 antibody therapy and treating a patient having psoriasis with extended dosing intervals after measuring at least one indicator from psoriasis patients before and during treatment with an IL-23 antibody is useful in the treatment of psoriasis.

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g.

Abstract: A method for predicting maintenance of response to IL-23 antibody therapy and treating a patient having psoriasis with extended dosing intervals after measuring at least one indicator from psoriasis patients before and during treatment with an IL-23 antibody is useful in the treatment of psoriasis.